A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )
Public ClinicalTrials.gov record NCT07526974. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat.
Study identification
- NCT ID
- NCT07526974
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Caliway Biopharmaceuticals Co., Ltd.
- Industry
- Enrollment
- 320 participants
Conditions and interventions
Conditions
Interventions
- CBL-514 Injection Drug
- 0.9% Sodium Chloride Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2026
- Primary completion
- Jul 31, 2027
- Completion
- Sep 30, 2027
- Last update posted
- Apr 13, 2026
2026 – 2027
United States locations
- U.S. sites
- 11
- U.S. states
- 11
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site 1 | Encinitas | California | 92024 | — |
| Investigational site 2 | Aventura | Florida | 33180 | — |
| Investigational Site 3 | Alpharetta | Georgia | 30005 | — |
| Investigational Site 4 | Hunt Valley | Maryland | 21030 | — |
| Investigational site 5 | Omaha | Nebraska | 68144 | — |
| Investigational site 6 | New York | New York | 10028 | — |
| Investigational Site 7 | Canal Winchester | Ohio | 43110 | — |
| Investigational site 8 | Nashville | Tennessee | 37215 | — |
| Investigational site 9 | Austin | Texas | 78759 | — |
| Investigational Site 10 | Arlington | Virginia | 22209 | — |
| Investigational Site 11 | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07526974, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 13, 2026 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07526974 live on ClinicalTrials.gov.